# data[].attributes.body
The study used odds ratios (ORs), with 95% confidence intervals (CIs), for glioma associated with statin use

# data[].attributes.body
Long-term statin use was associated with a reduced risk of glioma (OR = 0.76; 95% CI: 0.59–0.98; Table 2) compared with never users of statin.

This was related to treatment intensity (high-intensity treatment: OR = 0.71; 95% CI: 0.44–1.15; P-value: 0.041; Table 3).

The long-term statin treatment and the reduced risk of glioma was more pronounced among men aged ≤60 years (OR = 0.40; 95% CI: 0.17–0.91) compared with men aged 60+  years (OR = 0.71; 95% CI: 0.49–1.03).

An inverse association was also observed among women aged ≤60 years (OR = 0.28; 95% CI: 0.06–1.25), but not among women over age 60 years (OR = 1.23; 95% CI: 0.82–1.85).

# data[].attributes.body
Gaist, D., et al., 2013. Use of statins and risk of glioma: a nationwide case-control study in Denmark. British Journal of Cancer, vol. 108, no. 3, pp. 715.

# data[].attributes.body
Identified all patients aged 20 to 85 years with first diagnosis of histologically verified glioma

The cases were matched on birth year and sex with population controls (1:8 ratio)

The controls had to be alive and at risk for a first diagnosis of cancer

study subjects were classified as statin ever users  (≥ 2 prescriptions at defined daily doses ) and statin never users (no prescriptions for statins)

Duration of statin use was defined as the time period between the first and last statin prescription and classified as short duration (1–5 years before index date) or long duration (5 + years before index date)

# data[].attributes.body
To investigate the influence of statin use on the risk of glioma in a population

# data[].attributes.body
Long-term statin use may reduce the risk of glioma

the effect of long-term statin use may be more pronounced in both genders, among those ≤ 60 years of age

# data[].attributes.body
Statins have a protective effect on the risk of glioma